Who Paid My Doc
Ravikanth Chiravuri
Interventional Cardiology Aventura, FL Medical Doctor
NPI 1386845774 CMS profile 290118
2801 Ne 213Th St Ste 811, Ste 811, Aventura, FL 33180
General payments
$15,080
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$8,500
Through program year 2025, Ravikanth Chiravuri of Aventura, FL is reported in the CMS Open Payments database as having received $15,080 across 251 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $8,500 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 69th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $933 | 23 | |
| 2024 | General | $1,923 | 39 | |
| 2023 | General | $2,145 | 43 | |
| 2022 | General | $3,693 | 60 | |
| 2021 | General | $2,556 | 33 | |
| 2020 | General | $825 | 14 | |
| 2019 | General | $3,004 | 39 |
Beside peers
- Ravikanth Chiravuri
- Interventional Cardiology median
- Middle half of Interventional Cardiology
- National median
In program year 2025, general payments to Ravikanth Chiravuri were reported at $933. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.
Show as a table
| Year | Ravikanth Chiravuri | Interventional Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $3,004 | $1,097 | $329–$3,048 | $163 |
| 2020 | $825 | $473 | $161–$1,480 | $114 |
| 2021 | $2,556 | $677 | $233–$1,827 | $132 |
| 2022 | $3,693 | $978 | $333–$2,724 | $149 |
| 2023 | $2,145 | $1,136 | $382–$2,986 | $160 |
| 2024 | $1,923 | $1,181 | $395–$3,326 | $164 |
| 2025 | $933 | $1,092 | $366–$3,019 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
251 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Interventional Cardiology in Florida
Arthur Lee
Interventional Cardiology · Gainesville, FL
Santhosh Mathews
Interventional Cardiology · Bradenton, FL
Siddharth Wayangankar
Interventional Cardiology · Jacksonville, FL
Patrick Cambier
Interventional Cardiology · Trinity, FL
Zahid Amin
Interventional Cardiology · Orlando, FL
Rohit Amin
Interventional Cardiology · Pensacola, FL
Related records
Interventional Cardiology in Florida
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in Florida
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.